Verrica Pharmaceuticals Inc. (VRCA) Financials

VRCA Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 38.8 million 22.7 million
Dec. 31, 2025 47.1 million 22.4 million
Sept. 30, 2025 40.9 million 57.9 million
June 30, 2025 39.1 million 56.6 million

VRCA Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -9.2 million 897000
Dec. 31, 2025 -4.6 million 686000
Sept. 30, 2025 9.7 million 718000
June 30, 2025 -10.0 million 888000

VRCA Net Income

No data available :(

VRCA Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 20.6 million - 698000
Dec. 31, 2025 30.1 million - 1.6 million
Sept. 30, 2025 21.1 million 21.6 million 1.7 million
June 30, 2025 15.4 million 24.6 million 1.6 million

VRCA Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 10.7 million
Dec. 31, 2025 10.7 million
Sept. 30, 2025 9.5 million
June 30, 2025 9.5 million

VRCA Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 3.9 million 10.0 million -
Dec. 31, 2025 - 2.5 million 8.1 million 300000
Sept. 30, 2025 - 2.2 million 9.4 million -
June 30, 2025 - 1.8 million 8.9 million -

VRCA Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 5.0 million 889000
Dec. 31, 2025 5.1 million 1.4 million
Sept. 30, 2025 14.3 million 1.1 million
June 30, 2025 12.7 million 494000

VRCA Revenue by Segment
Graph available only for paid members. Upgrade to see it.

VRCA

Price: $5.63

52 week price:
3.28
9.82

Earnings Per Share: -1.10 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 337100

Market Capitalization: 64.3 million

Links: